Combination Drugs for Treating Metastatic Castration-resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair identifier:
NCT03012321 (

Treatment study for men with metastatic castration-resistant prostate cancer

Study Contact Information:

For additional information, please contact:

The study coordinator by phone: (312)695-1301 or by email: [email protected]


About the Study

The goal of this study is to compare the effectiveness of three different drug combinations to treat men with metastatic castration-resistant prostate cancer (mCRPR), who also have a mutation in a gene that affects DNA repair found through tumor testing. 

Type of Study

This is a randomized, open-label study. In a randomized study, participants are placed into one of the two study groups by chance. Neither patients nor their research doctor choose the group into which the participants are placed. In an open-label study, all patients will know which intervention or medication they are receiving during the study.

What the Study Involves

Participants will be assigned to one of four groups. All groups will receive their treatment in 28 day cycles.

Participants in single treatment groups may cross over to opposite single treatment groups if their tumor grows/disease progresses. Overall, the study goal is to determine whether the prostate cancer grows or not after treatment. Participants will be followed for up to 2 years.

Study Sites









New York

North Carolina



This Study is Open To:

Men 18 years or older may participate if they meet the following: 

This Study is Not Open To:

Men may not participate if they have the following:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.